CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Identification of S1PR4 as an immune modulator for favorable prognosis in HNSCC through machine learning.
Identification of S1PR4 as an immune modulator for favorable prognosis in HNSCC through machine learning.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
G 蛋白偶联受体(GPCR)是最大的膜蛋白家族,是重要的药理学靶点。更深入理解 GPCR 参与肿瘤微环境的方式,可能为癌症治疗提供新思路。本研究采用机器学习,根据 GPCR 将头颈部鳞状细胞癌(HNSCC)患者分为两种亚型。值得注意的是,这些亚型在预后、基因表达和免疫微环境方面存在显著差异,尤其是 CD8⁺ T 细胞浸润。S1PR4 是区分两种亚型的关键调节因子,在 HNSCC 中与 CD8⁺ T 细胞比例和细胞毒性呈正相关。该基因主要在 T 细胞中的 CX3CR1⁺CD8⁺ T 细胞中表达。上调 S1PR4 可增强 CAR-T 细胞治疗期间的 T 细胞功能,提示其在癌症免疫治疗中的潜力。这些发现凸显 S1PR4 作为有利预后免疫调节因子的作用,并为 HNSCC 治疗提供了潜在的 GPCR 靶向治疗选择。
G protein-coupled receptors (GPCRs) are the largest family of membrane proteins and play a critical role as pharmacological targets. An improved understanding of GPCRs' involvement in tumor microenvironment may provide new perspectives for cancer therapy.
This study used machine learning to classify head and neck squamous cell carcinoma (HNSCC) patients into two GPCR-based subtypes.
Notably, these subtypes showed significant differences in prognosis, gene expression, and immune microenvironment, particularly CD8 + T cell infiltration. S1PR4 emerged as a key regulator distinguishing the subtypes, positively correlated with CD8 + T cell proportion and cytotoxicity in HNSCC. It was predominantly expressed in CX3CR1 + CD8 + T cells among T cells. Upregulation of S1PR4 enhanced T cell function during CAR-T cell therapy, suggesting its potential in cancer immunotherapy.
These findings highlight S1PR4 as an immune modulator for favorable prognosis in HNSCC, and offer a potential GPCR-targeted therapeutic option for HNSCC treatment.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。